日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Prevalence, molecular characterization, and prognosis of c-Met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer

在真实世界非鳞状非小细胞肺癌患者队列中，c-Met蛋白过表达的患病率、分子特征和预后

期刊:Acta Oncologica
影响因子:2.2
doi:10.2340/1651-226X.2025.44344
Bar, Jair; Cai, Mona H; Choi, Yookyung Christy; Baijal, Shobhit; Zhao, Weilong; Liede, Alexander; Vasilopoulos, Athan; Roberts-Rapp, Lisa; Jiang, Fang; Simmons, Archana; Ratajczak, Christine; Lu, Shun; Ansell, Peter J; Camidge, D Ross
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

EGFR生物标志物检测方法的比较：对胶质母细胞瘤患者精准医疗的意义

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-18-3034
Lassman, Andrew B; Roberts-Rapp, Lisa; Sokolova, Irina; Song, Minghao; Pestova, Ekaterina; Kular, Rupinder; Mullen, Carolyn; Zha, Zheng; Lu, Xin; Gomez, Erica; Bhathena, Anahita; Maag, David; Kumthekar, Priya; Gan, Hui K; Scott, Andrew M; Guseva, Maria; Holen, Kyle D; Ansell, Peter J; van den Bent, Martin J
细胞生物学
EGF
EGFR
发表日期：2019
文献求助 收藏

Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma

在胶质母细胞瘤随机试验的筛查患者中观察到的表皮生长因子受体 (EGFR) 扩增率

期刊:Journal of Neuro-Oncology
影响因子:3.1
doi:10.1007/s11060-019-03222-y
Lassman, Andrew B; Aldape, Kenneth D; Ansell, Peter J; Bain, Earle; Curran, Walter J; Eoli, Marica; French, Pim J; Kinoshita, Manabu; Looman, Jim; Mehta, Minesh; Muragaki, Yoshihiro; Narita, Yoshitaka; Ocampo, Christopher; Roberts-Rapp, Lisa; Song, Minghao; Vogelbaum, Michael A; Walenkamp, Annemiek M E; Wang, Tony J C; Zhang, Peixin; van den Bent, Martin J
信号转导
细胞生物学
EGF
EGFR
发表日期：2019
文献求助 收藏

Potential mechanisms of resistance to venetoclax and strategies to circumvent it

维奈克拉耐药的潜在机制及规避策略

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-017-3383-5
Stephen K Tahir, Morey L Smith, Paul Hessler, Lisa Roberts Rapp, Kenneth B Idler, Chang H Park, Joel D Leverson, Lloyd T Lam
发表日期：2017
文献求助 收藏

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

depatuxizumab mafodotin (ABT-414) 单药治疗 EGFR 扩增复发性胶质母细胞瘤患者的疗效：一项多中心国际研究的结果

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-017-3451-1
van den Bent, Martin; Gan, Hui K; Lassman, Andrew B; Kumthekar, Priya; Merrell, Ryan; Butowski, Nicholas; Lwin, Zarnie; Mikkelsen, Tom; Nabors, Louis B; Papadopoulos, Kyriakos P; Penas-Prado, Marta; Simes, John; Wheeler, Helen; Walbert, Tobias; Scott, Andrew M; Gomez, Erica; Lee, Ho-Jin; Roberts-Rapp, Lisa; Xiong, Hao; Bain, Earle; Ansell, Peter J; Holen, Kyle D; Maag, David; Reardon, David A
细胞生物学
EGF
EGFR
发表日期：2017
文献求助 收藏

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

MCL-1 功能丧失使非霍奇金淋巴瘤细胞系对 BCL-2 选择性抑制剂维奈托克 (ABT-199) 敏感。

期刊:Blood Cancer Journal
影响因子:11.6
doi:10.1038/bcj.2016.12
Phillips, D C; Xiao, Y; Lam, L T; Litvinovich, E; Roberts-Rapp, L; Souers, A J; Leverson, J D
细胞生物学
淋巴瘤
发表日期：2016
文献求助 收藏

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

MCL-1 功能丧失使非霍奇金淋巴瘤细胞系对 BCL-2 选择性抑制剂维奈克拉 (ABT-199) 敏感

期刊:Blood Cancer Journal
影响因子:12.9
doi:10.1038/bcj.2015.88
D C Phillips, Y Xiao, L T Lam, E Litvinovich, L Roberts-Rapp, A J Souers, J D Leverson
免疫
细胞生物学
淋巴瘤
肿瘤细胞
发表日期：2015
文献求助 收藏

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

MCL-1 是乳腺癌细胞存活的关键决定因素：利用高选择性小分子抑制剂验证 MCL-1 依赖性

期刊:Molecular Cancer Therapeutics
影响因子:5.3
doi:10.1158/1535-7163.MCT-14-0928
Yu Xiao, Paul Nimmer, George S Sheppard, Milan Bruncko, Paul Hessler, Xin Lu, Lisa Roberts-Rapp, William N Pappano, Steven W Elmore, Andrew J Souers, Joel D Leverson, Darren C Phillips
肿瘤
乳腺癌
肿瘤细胞
发表日期：2015
文献求助 收藏

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

ilorasertib（一种双重 Aurora/VEGF 受体激酶抑制剂）治疗血液系统恶性肿瘤患者的 1 期剂量递增试验

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-015-0242-6
Garcia-Manero, Guillermo; Tibes, Raoul; Kadia, Tapan; Kantarjian, Hagop; Arellano, Martha; Knight, Emily A; Xiong, Hao; Qin, Qin; Munasinghe, Wijith; Roberts-Rapp, Lisa; Ansell, Peter; Albert, Daniel H; Oliver, Brian; McKee, Mark D; Ricker, Justin L; Khoury, Hanna Jean
肿瘤
肿瘤免疫
信号转导
EGF
VEGF
发表日期：2015
文献求助 收藏